SV2002000294A - PIRIDO [2,3-D] PIRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES REF. PCA 84-01-CA / 20131 / BB - Google Patents
PIRIDO [2,3-D] PIRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES REF. PCA 84-01-CA / 20131 / BBInfo
- Publication number
- SV2002000294A SV2002000294A SV2001000294A SV2001000294A SV2002000294A SV 2002000294 A SV2002000294 A SV 2002000294A SV 2001000294 A SV2001000294 A SV 2001000294A SV 2001000294 A SV2001000294 A SV 2001000294A SV 2002000294 A SV2002000294 A SV 2002000294A
- Authority
- SV
- El Salvador
- Prior art keywords
- replaced
- group
- po3r13r14
- compounds
- lower rent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
SE DESCRIBEN COMPUESTOS DE UNA FORMULA EN LA CUAL:R2, R7, R13, R14, Y R15 SON, INDEPENDIENTEMENTE, HIDROGENO O ALQUILO INFERIOR SUSTITUIDO O SIN SUSTITUIR, ALQUENILO INFERIOR SUSTITUIDO O SIN SUSTITUIR, O BIEN -(CH2)NR12 SUSTITUIDO O SIN SUSTITUIR;R5 ES HALOGENO, CIANO, NITRO, -R9, -NR9R10, O BIEN OR9;R6 ES HALOGENO, CIANO, NITRO, -R9, -NR9R10, -OR9, -CO2R9, -COR9, -CONR9, NR9COR10, ALQUENILO INFERIOR SUSTITUIDO O SIN SUSTITUIR, O ALQUINILO INFERIOR SUSTITUIDO O SIN SUSTITUIR;R8 ES -CO2R13, -COR13, -CONR13R14, -CSNR13R14, C(NR13)NR14R15, SO3R13, -SO2R13, -SO2NR13R14, -PO3R13R14, -POR13R14, -PO(NR13R14)2;R9 Y R10 SON, INDEPENDIENTEMENTE, HIDROGENO O ALQUILO INFERIOR SUSTITUIDO O SIN SUSTITUIR;R11 ES UN GRUPO HETEROARILO O UN GRUPO HETEROCICLICO; R12 ES UN GRUPO CICLOALQUILO, UN GRUPO HETEROCICLICO, UN GRUPO ARILO, O UN GRUPO HETEROARILO; YN VALE O, 1, 2 O 3.ESTOS COMPUESTOS Y SUS COMPOSICIONES FARMACEUTICAS SON UTILES PARA TRATAR TRASTORNOS PROLIFERATIVOS CELULARES, TALES COMO CANCER Y RESTENOSIS. ESTOS COMPUESTOS SON POTENTES INHIBIDORES DE CDKS Y DE CINASAS MEDIADAS POR FACTOR DE CRECIMIENTO.COMPOUNDS OF A FORMULA ARE DESCRIBED IN WHICH: R2, R7, R13, R14, and R15 ARE, INDEPENDENTLY, HYDROGEN OR LOWER RENT REPLACED OR NOT REPLACED, LOWER RENT REPLACED OR NOT REPLACED, OR (CH2) WITHOUT REPLACED REPLACE; R5 IS HALOGEN, CYAN, NITRO, -R9, -NR9R10, OR OR9; R6 IS HALOGEN, CYAN, NITRO, -R9, -NR9R10, -OR9, -CO2R9, -COR9, -CONR9, NR9COR10, ALQUEN REPLACED OR NOT REPLACED, OR LOWER RENT REPLACED OR NOT REPLACED; R8 ES -CO2R13, -COR13, -CONR13R14, -CSNR13R14, C (NR13) NR14R15, SO3R13, -SO2R13, -SO2NR13R14, -PO3R13R14, -PO3R13R14, -PO3R13R14, -PO3R13R14, -PO3R13R14 NR13R14) 2; R9 AND R10 ARE, INDEPENDENTLY, HYDROGEN OR LOWER RENT SUBSTITUTED OR UNTITUDED; R11 IS A HETEROARILE GROUP OR A HETEROCICLICAL GROUP; R12 IS A CICLOALQUILO GROUP, A HETEROCICLICAL GROUP, AN ARILO GROUP, OR A HETEROARILO GROUP; NO VALUE, 1, 2 OR 3. THESE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS ARE USEFUL TO TREAT CELLULAR PROLIFERATIVE DISORDERS, SUCH AS CANCER AND RESTENOSIS. THESE COMPOUNDS ARE POWERFUL INHIBITORS OF CDKS AND KINASES MEASURED BY GROWTH FACTOR.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17826100P | 2000-01-25 | 2000-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2002000294A true SV2002000294A (en) | 2002-07-16 |
Family
ID=22651853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2001000294A SV2002000294A (en) | 2000-01-25 | 2001-01-24 | PIRIDO [2,3-D] PIRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES REF. PCA 84-01-CA / 20131 / BB |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1254137A1 (en) |
| JP (1) | JP4047010B2 (en) |
| KR (1) | KR20020065939A (en) |
| CN (1) | CN1395578A (en) |
| AP (1) | AP2002002586A0 (en) |
| AR (1) | AR030044A1 (en) |
| AU (1) | AU2542501A (en) |
| BG (1) | BG106850A (en) |
| BR (1) | BR0107751A (en) |
| CA (1) | CA2397961C (en) |
| CO (1) | CO5261549A1 (en) |
| CR (1) | CR6706A (en) |
| CZ (1) | CZ20022475A3 (en) |
| DZ (1) | DZ3266A1 (en) |
| EA (1) | EA200200643A1 (en) |
| EE (1) | EE200200405A (en) |
| GT (1) | GT200100016A (en) |
| HN (1) | HN2001000013A (en) |
| HU (1) | HUP0204141A3 (en) |
| IL (1) | IL150545A0 (en) |
| IS (1) | IS6443A (en) |
| MA (1) | MA26868A1 (en) |
| MX (1) | MXPA02007221A (en) |
| NO (1) | NO20023527L (en) |
| OA (1) | OA12161A (en) |
| PA (1) | PA8510701A1 (en) |
| PE (1) | PE20011066A1 (en) |
| PL (1) | PL356802A1 (en) |
| SK (1) | SK10632002A3 (en) |
| SV (1) | SV2002000294A (en) |
| TN (1) | TNSN01014A1 (en) |
| WO (1) | WO2001055147A1 (en) |
| YU (1) | YU50402A (en) |
| ZA (1) | ZA200205879B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| WO2002059083A2 (en) | 2000-10-23 | 2002-08-01 | Smithkline Beecham Corporation | Novel compounds |
| PE20030008A1 (en) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | DUAL INHIBITORS OF PDE 7 AND PDE 4 |
| JP4603268B2 (en) | 2002-04-19 | 2010-12-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | New compounds |
| RS20050363A (en) * | 2002-11-28 | 2007-11-15 | Schering Aktiengesellschaft, | Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents |
| US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| TW200502236A (en) | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| FR2873118B1 (en) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS |
| CA2579406A1 (en) * | 2004-09-21 | 2006-03-30 | F.Hoffmann-La Roche Ag | 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors |
| UY29439A1 (en) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | NEW COMPOUNDS |
| US20090137550A1 (en) | 2005-03-25 | 2009-05-28 | Glaxo Group Limited | Novel Compounds |
| SG160438A1 (en) | 2005-03-25 | 2010-04-29 | Glaxo Group Ltd | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5- d]pyrimidin-2(1h)-one derivatives |
| PE20100737A1 (en) | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | NEW COMPOUNDS |
| FR2887882B1 (en) | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
| CA2614443C (en) * | 2005-07-21 | 2011-03-22 | F. Hoffmann-La Roche Ag | Pyrido [2,3-d] pyrimidine-2,4-diamine compounds as ptp1b inhibitors |
| BRPI0614804A2 (en) | 2005-08-09 | 2011-04-12 | Irm Llc | compounds and compositions as protein kinase inhibitors |
| FR2896246B1 (en) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
| EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| JO2985B1 (en) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | MAPK/ERK Kinase Inhibitors |
| FR2910813B1 (en) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| JP5697601B2 (en) * | 2008-12-01 | 2015-04-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 2,5-Diamino-substituted pyrido [4,3-D] pyrimidines as autotaxin inhibitors against cancer |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| EP2968331B1 (en) * | 2013-03-14 | 2020-07-01 | Icahn School of Medicine at Mount Sinai | Pyrimidine compounds as kinase inhibitors |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| KR101671404B1 (en) * | 2014-09-02 | 2016-11-02 | 한국원자력의학원 | Pyrimidine derivatives having anti-cancer effect, combination therapeutic effect with radiation, and anti-diabetic effect, and PPAR activity, and medical use thereof |
| CN107286180B (en) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | Heteropyridopyrimidinone derivatives as CDK inhibitors and their applications |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE190978T1 (en) * | 1994-11-14 | 2000-04-15 | Warner Lambert Co | 6-ARYL-PYRIDO(2,3-D)PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING CELL PRODUCTION CAUSED BY PROTEIN TYROSINE KINASE |
| IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| KR20010043829A (en) * | 1998-05-26 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Bicyclic Pyrimidines and Bicyclic 3,4-Dihydropyrimidines as Inhibitors of Cellular Proliferation |
-
2001
- 2001-01-23 CN CN01804048A patent/CN1395578A/en active Pending
- 2001-01-23 CZ CZ20022475A patent/CZ20022475A3/en unknown
- 2001-01-23 PA PA20018510701A patent/PA8510701A1/en unknown
- 2001-01-23 BR BR0107751-1A patent/BR0107751A/en not_active IP Right Cessation
- 2001-01-23 SK SK1063-2002A patent/SK10632002A3/en not_active Application Discontinuation
- 2001-01-23 YU YU50402A patent/YU50402A/en unknown
- 2001-01-23 AR ARP010100285A patent/AR030044A1/en not_active Application Discontinuation
- 2001-01-23 MX MXPA02007221A patent/MXPA02007221A/en not_active Application Discontinuation
- 2001-01-23 AU AU25425/01A patent/AU2542501A/en not_active Abandoned
- 2001-01-23 JP JP2001561006A patent/JP4047010B2/en not_active Expired - Fee Related
- 2001-01-23 EA EA200200643A patent/EA200200643A1/en unknown
- 2001-01-23 IL IL15054501A patent/IL150545A0/en unknown
- 2001-01-23 PE PE2001000072A patent/PE20011066A1/en not_active Application Discontinuation
- 2001-01-23 DZ DZ013266A patent/DZ3266A1/en active
- 2001-01-23 HU HU0204141A patent/HUP0204141A3/en unknown
- 2001-01-23 OA OA1200200213A patent/OA12161A/en unknown
- 2001-01-23 WO PCT/IB2001/000069 patent/WO2001055147A1/en not_active Ceased
- 2001-01-23 GT GT200100016A patent/GT200100016A/en unknown
- 2001-01-23 EP EP01900591A patent/EP1254137A1/en not_active Withdrawn
- 2001-01-23 PL PL01356802A patent/PL356802A1/en not_active Application Discontinuation
- 2001-01-23 KR KR1020027009516A patent/KR20020065939A/en not_active Ceased
- 2001-01-23 EE EEP200200405A patent/EE200200405A/en unknown
- 2001-01-23 AP APAP/P/2002/002586A patent/AP2002002586A0/en unknown
- 2001-01-23 CA CA002397961A patent/CA2397961C/en not_active Expired - Fee Related
- 2001-01-24 SV SV2001000294A patent/SV2002000294A/en not_active Application Discontinuation
- 2001-01-24 TN TNTNSN01014A patent/TNSN01014A1/en unknown
- 2001-01-24 HN HN2001000013A patent/HN2001000013A/en unknown
- 2001-01-24 CO CO01005268A patent/CO5261549A1/en not_active Application Discontinuation
-
2002
- 2002-06-20 BG BG106850A patent/BG106850A/en unknown
- 2002-06-25 IS IS6443A patent/IS6443A/en unknown
- 2002-07-17 CR CR6706A patent/CR6706A/en not_active Application Discontinuation
- 2002-07-22 MA MA26736A patent/MA26868A1/en unknown
- 2002-07-23 ZA ZA200205879A patent/ZA200205879B/en unknown
- 2002-07-24 NO NO20023527A patent/NO20023527L/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2002000294A (en) | PIRIDO [2,3-D] PIRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES REF. PCA 84-01-CA / 20131 / BB | |
| MXPA04006271A (en) | Indolinone derivatives useful as protein kinase inhibitors. | |
| CY1118096T1 (en) | OPTIONAL RECEPTORS ADJUSTERS | |
| UA84318C2 (en) | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists, pharmaceutical composition based thereon | |
| PE20040914A1 (en) | PYRROLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF TYROSINE KINASES | |
| CR9650A (en) | DERIVATIVES OF TIENOPIRIMIDINE AND TIENOPIRIDINE AS INHIBITORS OF THYROSINE KINASE 3 TYPE FMS | |
| ATE554087T1 (en) | NEW KINASE INHIBITORS | |
| DK1333833T3 (en) | New trisubstituted 8H-pyridol [2,3-d] pyrimidin-7-one compound for the treatment of CSBP / RK / p38 kinase-mediated diseases | |
| PE20060555A1 (en) | PIRROL-OXINDOL DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | |
| ECSP034924A (en) | Substituted derivatives of 1-oxa-2,8-daza-spiro [4,5] dec-2-eno | |
| CL2011001129A1 (en) | Compounds derived from dihydro-tetraazbenzoazulenes alkylcyclohexyleters, v1a receptor antagonists; preparation procedure; pharmaceutical composition; and use in the treatment of dysmenorrhea, male or female sexual dysfunction, hypertension, anxiety, schizophrenia, among others. | |
| CR9649A (en) | AMINOPIRIMIDINS AS MODULAR CINASE | |
| TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| MXPA05007115A (en) | Novel cb 1 receptor inverse agonists. | |
| EP1233951A4 (en) | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors | |
| DE602004027288D1 (en) | Thienopyrazole | |
| BRPI0417520A (en) | Substituted 1h-pyrrolo [3,2-b, 3,2-c, and 2,3-c] pyridine-2-carboxamides and analogues reported as inhibitors of i-epsilon casein kinase | |
| DE60023025D1 (en) | 3,4-DIHYDRO- (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS | |
| UA95230C2 (en) | SUBSTITUTED DIHYDRO-PYRIMIDO[4,5-d]PYRIMIDINES, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| PL374019A1 (en) | Benzoxazine derivatives as 5-ht6 modulators and uses thereof | |
| EP1235814A4 (en) | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS | |
| EA200600688A1 (en) | ARYLINDENPYRIDINES AND ARYLINDENPYRIMIDINES AND THEIR APPLICATION AS ANTAGONISTS OF A2A Adenosine Receptor | |
| PL375259A1 (en) | Derivatives of pyridinalkyl-amonoalkyl-1h-indole inhibiting receptors 5-ht and recapture of serotonin which can be used as antidepressant and anxiolitic | |
| CL2004001431A1 (en) | COMPOUNDS DERIVED FROM 1- (ALQUILAMINOALQUIL- / PIRROLIDIN- / PIPERIDINIL) -2,2-DIFENYLACETAMIDE, ANTAGONISTS OF THE MUSCARINIC RECEIVER; PREPARATION PROCEDURE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMBINATION AND USE OF | |
| EP1988902A4 (en) | Piperazine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse |